Chugai Pharmaceutical Co. Ltd., of Tokyo, and Eli Lilly and Co., of Indianapolis, said they entered a license agreement for OWL-833, Chugai's oral non-peptidic GLP-1 receptor agonist, which is a phase I-ready asset that is being studied for the treatment of type 2 diabetes.